The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates

被引:25
作者
Al-Maskari, Fatma [1 ]
El-Sadig, Mohammed [1 ]
Norman, John N. [1 ]
机构
[1] United Arab Emirates Univ, Dept Community Med, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
关键词
D O I
10.1186/1475-2840-6-24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetes Mellitus (DM) is a major public health problem in the UAE with a prevalence rate reaching 24% in national citizens and 17.4% in expatriates. The aim of this study was to determine the prevalence and risk factors of macrovascular complications among diabetic patients in the Al-Ain district of the United Arab Emirates (UAE). Methods: The study was part of a general cross-sectional survey carried out to assess the prevalence of diabetes (DM) complications among known diabetic patients in Al-Ain District, UAE. Patients were randomly selected during 2003/2004. Patients completed an interviewer-administered questionnaire carried out by treating doctors and underwent a complete medical assessment including measurement of height, weight, blood pressure and examination for evidence of macrovascular complications. A standard ECG was recorded and blood samples were taken to document fasting blood sugar, glycosylated haemoglobin (HbA(IC)) and lipid profile. Results: A sample of 513 diabetic patients was selected with a mean age of 53 years (SD +/- 13.01). Overall, 29.5% of DM patients had evidence of macrovascular complications: 11.6% (95% CI: 8.8-14.4) of patients had peripheral vascular disease (PVD), 14.4% (95% CI: 11.3-17.5) had a history of coronary artery disease (CAD) and 3.5% (95% CI: 1.9-5.1%) had cerebrovascular disease (CVD). Of the total population surveyed 35% (95% CI: 30.8-39) had hypertension. The analysis showed that macrovascular complications in diabetic patients were more common among males, increased with age, were more common among hypertensive patients and its prevalence increased steadily with duration of DM. Conclusion: Our data revealed a significant association between hypertension and presence of macrovascular disease among diabetic patients. However, the risk of CAD in the UAE was relatively low compared to that seen in patients in other geographical settings. In addition, a lack of correlation between macrovascular disease and glycemic control among patients with DM was observed.
引用
收藏
页数:7
相关论文
共 27 条
  • [11] RISK-FACTORS FOR MACROVASCULAR DISEASE IN DIABETES-MELLITUS - THE LONDON FOLLOW-UP TO THE WHO MULTINATIONAL STUDY OF VASCULAR-DISEASE IN DIABETICS
    MORRISH, NJ
    STEVENS, LK
    FULLER, JH
    JARRETT, RJ
    KEEN, H
    [J]. DIABETOLOGIA, 1991, 34 (08) : 590 - 594
  • [12] Risk of macrovascular and microvascular complications in Type 2 diabetes - Results of longitudinal study design
    Nazimek-Siewniak, B
    Moczulski, D
    Grzeszczak, W
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2002, 16 (04) : 271 - 276
  • [13] Cost of managing complications resulting from type 2 diabetes mellitus in Canada
    O'Brien, JA
    Patrick, AR
    Caro, JJ
    [J]. BMC HEALTH SERVICES RESEARCH, 2003, 3 (1) : 7
  • [14] THE INFLUENCE OF BODY-FAT DISTRIBUTION ON THE INCIDENCE OF DIABETES-MELLITUS - 13.5 YEARS OF FOLLOW-UP OF THE PARTICIPANTS IN THE STUDY OF MEN BORN IN 1913
    OHLSON, LO
    LARSSON, B
    SVARDSUDD, K
    WELIN, L
    ERIKSSON, H
    WILHELMSEN, L
    BJORNTORP, P
    TIBBLIN, G
    [J]. DIABETES, 1985, 34 (10) : 1055 - 1058
  • [15] Park K, 2002, PARKS TXB PREVENTIVE
  • [16] Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women:: a cross-sectional study
    Petersson, Helena
    Daryani, Achraf
    Riserus, Ulf
    [J]. CARDIOVASCULAR DIABETOLOGY, 2007, 6 (1)
  • [17] Promotion CfCDPaH, BEH RISK FACT SURV S
  • [18] Sagittal abdominal diameter is a strong anthropometric marker of insulin resistance and hyperproinsulinemia in obese men
    Risérus, U
    Arnlöv, J
    Brismar, K
    Zethelius, B
    Berglund, L
    Vessby, B
    [J]. DIABETES CARE, 2004, 27 (08) : 2041 - 2046
  • [19] STEINER G, 1981, DIABETES, V30, P1
  • [20] TAN MH, 1995, CLIN INVEST MED, V18, P240